Literature DB >> 25998292

Prevention and reversal of type 1 diabetes--past challenges and future opportunities.

Jay S Skyler1.   

Abstract

Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize-potentially even reverse-the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in β-cell function compared with randomized control groups, while others have failed to slow the decline in β-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998292     DOI: 10.2337/dc15-0349

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

1.  Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus.

Authors:  Raghu Ganugula; Meenakshi Arora; Patcharawalai Jaisamut; Ruedeekorn Wiwattanapatapee; Heather G Jørgensen; Vinod P Venkatpurwar; Beiyan Zhou; Aline Rodrigues Hoffmann; Rita Basu; Shaodong Guo; Naga Venkata Ravi Kumar Majeti
Journal:  Br J Pharmacol       Date:  2017-05-30       Impact factor: 8.739

2.  Longitudinal proteomics analysis in the immediate microenvironment of islet allografts during progression of rejection.

Authors:  Oscar Alcazar; Luis F Hernandez; Ernesto S Nakayasu; Paul D Piehowski; Charles Ansong; Midhat H Abdulreda; Peter Buchwald
Journal:  J Proteomics       Date:  2020-05-20       Impact factor: 4.044

3.  Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.

Authors:  Emanuele Bosi; David C Boulware; Dorothy J Becker; Jane H Buckner; Susan Geyer; Peter A Gottlieb; Courtney Henderson; Amanda Kinderman; Jay M Sosenko; Andrea K Steck; Polly J Bingley
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

Review 4.  Rationally designed small molecules to prevent type 1 diabetes.

Authors:  David A Ostrov; Peter A Gottlieb; Aaron W Michels
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-04       Impact factor: 3.243

5.  Engineering immunomodulatory biomaterials for type 1 diabetes.

Authors:  C L Stabler; Y Li; J M Stewart; B G Keselowsky
Journal:  Nat Rev Mater       Date:  2019-05-17       Impact factor: 66.308

Review 6.  Should There be Concern About Autoimmune Diabetes in Adults? Current Evidence and Controversies.

Authors:  Jakob Appel Østergaard; Esben Laugesen; R David Leslie
Journal:  Curr Diab Rep       Date:  2016-09       Impact factor: 4.810

7.  Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction.

Authors:  Jinshui Chen; Yun Song; Damir Bojadzic; Alejandro Tamayo-Garcia; Ana Marie Landin; Bonnie B Blomberg; Peter Buchwald
Journal:  J Med Chem       Date:  2017-10-25       Impact factor: 7.446

Review 8.  Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.

Authors:  Connor J Dwyer; Natasha C Ward; Alberto Pugliese; Thomas R Malek
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

Review 9.  Insulitis in the pathogenesis of type 1 diabetes.

Authors:  Alberto Pugliese
Journal:  Pediatr Diabetes       Date:  2016-07       Impact factor: 4.866

10.  Combined intervention for the tertiary prevention of type 1 diabetes.

Authors:  Eiji Kawasaki
Journal:  J Diabetes Investig       Date:  2015-09-16       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.